The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

NCT06520345 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: 177Lu-TLX591
DRUG: Enzalutamide
DRUG: Abiraterone
DRUG: Docetaxel

Sponsor

Telix Pharmaceuticals (Innovations) Pty Limited